These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 16862520)

  • 1. Aspects of the laboratory identification of von Willebrand disease in women.
    Kouides PA
    Semin Thromb Hemost; 2006 Jul; 32(5):480-4. PubMed ID: 16862520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current understanding of von Willebrand's disease in women - some answers, more questions.
    Kouides PA
    Haemophilia; 2006 Jul; 12 Suppl 3():143-51. PubMed ID: 16684010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
    Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of von Willebrand disease in women with iron deficiency anaemia and menorrhagia in Taiwan.
    Chen YC; Chao TY; Cheng SN; Hu SH; Liu JY
    Haemophilia; 2008 Jul; 14(4):768-74. PubMed ID: 18498402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lower limit of assay sensitivity: an under-recognised and significant problem in von Willebrand disease identification and classification.
    Favaloro EJ; Bonar R; Marsden K
    Clin Lab Sci; 2008; 21(3):178-83. PubMed ID: 18678140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet von Willebrand factor determination does not improve the diagnosis of patients with suspected Type 1 von Willebrand disease.
    Shihong I; Morris D; Konkle BA
    Haemophilia; 2009 Jan; 15(1):131-4. PubMed ID: 18976254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA).
    Nichols WL; Hultin MB; James AH; Manco-Johnson MJ; Montgomery RR; Ortel TL; Rick ME; Sadler JE; Weinstein M; Yawn BP
    Haemophilia; 2008 Mar; 14(2):171-232. PubMed ID: 18315614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Laboratory identification of von Willebrand disease: technical and scientific perspectives.
    Favaloro EJ
    Semin Thromb Hemost; 2006 Jul; 32(5):456-71. PubMed ID: 16862518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Laboratory diagnosis and molecular classification of von Willebrand disease.
    Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
    Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis of inherited von Willebrand disease: a clinical perspective.
    Federici AB
    Semin Thromb Hemost; 2006 Sep; 32(6):555-65. PubMed ID: 16977566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of recessive severe type 1 and 3 von Willebrand Disease (VWD), asymptomatic heterozygous carriers versus bloodgroup O-related von Willebrand factor deficiency, and dominant type 1 VWD.
    Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van de Velde A; van Vliet H
    Clin Appl Thromb Hemost; 2006 Jul; 12(3):277-95. PubMed ID: 16959681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2B or not 2B? Disparate discrimination of functional VWF discordance using different assay panels or methodologies may lead to success or failure in the early identification of type 2B VWD.
    Favaloro EJ; Bonar R; Meiring M; Street A; Marsden K;
    Thromb Haemost; 2007 Aug; 98(2):346-58. PubMed ID: 17721617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distribution of von Willebrand factor levels in young women with and without bleeding symptoms: influence of ABO blood group and promoter haplotypes.
    Lethagen S; Hillarp A; Ekholm C; Mattson E; Halldén C; Friberg B
    Thromb Haemost; 2008 Jun; 99(6):1013-8. PubMed ID: 18521502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Laboratory diagnosis of von Willebrand's disorder: quality and diagnostic improvements driven by peer review in a multilaboratory test process.
    Favaloro EJ; Bonar R; Kershaw G; Sioufi J; Hertzberg M; Street A; Lloyd J; Marsden K;
    Haemophilia; 2004 May; 10(3):232-42. PubMed ID: 15086320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Women and von Willebrand disease: controversies in diagnosis and management.
    Kadir RA; Chi C
    Semin Thromb Hemost; 2006 Sep; 32(6):605-15. PubMed ID: 16977570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cold storage of citrated whole blood induces drastic time-dependent losses in factor VIII and von Willebrand factor: potential for misdiagnosis of haemophilia and von Willebrand disease.
    Böhm M; Täschner S; Kretzschmar E; Gerlach R; Favaloro EJ; Scharrer I
    Blood Coagul Fibrinolysis; 2006 Jan; 17(1):39-45. PubMed ID: 16607078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The molecular analysis of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organisation Haemophilia Genetics Laboratory Network.
    Keeney S; Bowen D; Cumming A; Enayat S; Goodeve A; Hill M;
    Haemophilia; 2008 Sep; 14(5):1099-111. PubMed ID: 18637846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3.
    Michiels JJ; Gadisseur A; van der Planken M; Schroyens W; van de Velden A; Berneman Z
    Semin Thromb Hemost; 2006 Sep; 32(6):636-45. PubMed ID: 16977574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PFA-100 monitoring of von Willebrand factor (VWF) responses to desmopressin (DDAVP) and factor VIII/VWF concentrate substitution in von Willebrand disease type 1 and 2.
    van Vliet HH; Kappers-Klunne MC; Leebeek FW; Michiels JJ
    Thromb Haemost; 2008 Sep; 100(3):462-8. PubMed ID: 18766263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.